Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
Weighing Conditioning Regimens for Patients With CML Undergoing Transplant
Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...
Eculizumab Reduces Hemolysis and Transfusion Dependency in Patients With Cold Agglutin Disease
Treatment with eculizumab, an inhibitor of the terminal complement pathway, reduced hemolysis and transfusion-dependence in patients with cold agglutin disease (CAD). However, it had...
Phlebotomy and Hydroxyurea Are Underused in Patients With Polycythemia Vera
Treatment with phlebotomy or hydroxyurea was associated with lower mortality among older patients with polycythemia vera (PV) who were considered at high thrombotic risk,...
Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...
Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...
In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients
In a study published in Blood Advances, investigators reviewed data from a large cohort of patients who had undergone a hematopoietic cell transplantation (HCT)...
Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma
Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...
Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs
Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...
Current Issue
March 2019, Volume 5, Issue 4
This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.
